Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm

Leukemia Research

Volumn 39, Issue 4, 2015, Pages 471-478

  Yin, Li hui ^a   Zheng, Xiao qun ^b,c   Li, Hai ying ^a   Bi, Lai xi ^a   Shi, Yi fen ^a   Ye, Ai fang ^a   Wu, Jian bo ^a   Gao, Shen meng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Epigenetics; MiRNA; MPN

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; JANUS KINASE 2; LUCIFERASE; MICRORNA 375; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; JAK2 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN375 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BINDING SITE; BONE MARROW DERIVED MONONUCLEAR CELL; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; APOPTOSIS; CHROMATIN IMMUNOPRECIPITATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MICRORNAS; MUTATION; MYELOPROLIFERATIVE DISORDERS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84925212857     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.01.009     Document Type: Article

References (35)

1. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011, 29:573-582.
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
3. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
4. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
5. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
6. Vainchenker W., Delhommeau F., Constantinescu S.N., Bernard O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118:1723-1735.
7. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013, 369:2391-2405.
8. Capello D., Deambrogi C., Rossi D., Lischetti T., Piranda D., Cerri M., et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2008, 141:504-511.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
10. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
11. Li Y., Gao L., Luo X., Wang L., Gao X., Wang W., et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 2013, 121:499-509.
12. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
13. Poy M.N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., Macdonald P.E., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432:226-230.
14. Ye X.M., Zhu H.Y., Bai W.D., Wang T., Wang L., Chen Y., et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer 2014, 14:134.
15. He X.X., Chang Y., Meng F.Y., Wang M.Y., Xie Q.H., Tang F., et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 2012, 31:3357-3369.
16. Wang F., Li Y., Zhou J., Xu J., Peng C., Ye F., et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011, 179:2580-2588.
17. Lippert E., Boissinot M., Kralovics R., Girodon F., Dobo I., Praloran V., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108:1865-1867.
18. Guerini V., Barbui V., Spinelli O., Salvi A., Dellacasa C., Carobbio A., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22:740-747.
19. Akada H., Akada S., Gajra A., Bair A., Graziano S., Hutchison R.E., et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood 2012, 119:3779-3789.
20. Reid C.D. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Rev 1987, 1:133-140.
21. Yan J.W., Lin J.S., He X.X. The emerging role of miR-375 in cancer. Int J Cancer 2014, 135:1011-1018.
22. Isozaki Y., Hoshino I., Nohata N., Kinoshita T., Akutsu Y., Hanari N., et al. Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 2012, 41:985-994.
23. Gao S.M., Chen C.Q., Wang L.Y., Hong L.L., Wu J.B., Dong P.H., et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol 2013, 41:261-270.
24. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Invest Drugs 2007, 16:1111-1120.
25. Ding L., Xu Y., Zhang W., Deng Y., Si M., Du Y., et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010, 20:784-793.
26. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091:151-169.
27. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I. Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
28. Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61:33-42.
29. Chu M., Chang Y., Li P., Guo Y., Zhang K., Gao W. Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells. Oncol Rep 2014, 31:34-40.
30. Wernig G., Gonneville J.R., Crowley B.J., Rodrigues M.S., Reddy M.M., Hudon H.E., et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008, 111:3751-3759.
31. Tao J. Zhao X. c-MYC-miRNA circuitry: A central regulator of aggressive B-cell malignancies. Cell Cycle 2014, 13:191-198.
32. Nam S., Wen W., Schroeder A., Herrmann A., Yu H., Cheng X., et al. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 2013, 7:369-378.
33. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006, 66:1277-1281.
34. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012, 53:123-129.
35. Xiong H., Du W., Zhang Y.J., Hong J., Su W.Y., Tang J.T., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 2012, 51:174-184.